Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study
Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis o...
Gespeichert in:
| Veröffentlicht in: | Renal failure 2021, Vol.43 (1), p.1569-1576 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1576 |
|---|---|
| container_issue | 1 |
| container_start_page | 1569 |
| container_title | Renal failure |
| container_volume | 43 |
| creator | Dong, Gui-Ying Qin, Jun-Ping An, Youzhong Kang, Yan Yu, Xiangyou Zhao, Mingyan Ma, Xiaochun Ai, Yuhang Xu, Yuan Xi, Xiuming Qian, Chuanyun Wu, Dawei Sun, Renhua Li, Shusheng Hu, Zhenjie Cao, Xiangyuan Zhou, Fachun Jiang, Li Lin, Jiandong Chen, Erzhen Qin, Tiehe He, Zhenyang Zhu, Jihong Du, Bin |
| description | Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis of the two types of patients is similar in the ICU remains unclear.
According to the absolute and relative increase of Scr, AKI stage 1 and stage 3 patients were divided into stage 1a and 1b, stage 3a and 3b groups, respectively. Their demographics, laboratory results, clinical characteristics, and outcomes were analyzed retrospectively.
Of the 345 eligible cases, we analyzed stage 1 because stage 3a group had only one patient. Using 53 or 61.88 µmol/L as the reference Scr (Scr
ref
), no significant differences were observed in ICU mortality (P
53
=0.076, P
61.88
=0.070) or renal replacement therapy (RRT) ratio, (P
53
=0.356, P
61.88
=0.471) between stage 1a and 1b, but stage 1b had longer ICU length of stay (LOS) than stage 1a (P
53 |
| doi_str_mv | 10.1080/0886022X.2021.1997761 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8648037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_49dfc484974744768236abafd1918d4f</doaj_id><sourcerecordid>2606930405</sourcerecordid><originalsourceid>FETCH-LOGICAL-d3561-14781bc45a867c37139517dec2951b0f5495f6729f11b8169e4f672d9b5ec96e3</originalsourceid><addsrcrecordid>eNpdkstuEzEUhkcIRNPCIyBZYsMmwbfxhQWiClCiVuoCKrGzPB5P4sgZD7ankK4Q78KL8SR4SEAqK9--88nH_qvqGYILBAV8CYVgEOPPCwwxWiApOWfoQTVDNa7nDFL5sJpNzHyCTqrTlLYQolpw_Lg6IbQUIyJn1c-b7Ly7c_0aRGu8Tsl1zujsQg9y-PX9h_02-BBtmZmNjtpkG13KziSg-xYMMaz7kFwCoQOXb1cX1x-XEZxfrkAam3UM45BeAV3UOYY0WJPdrS2F2u-PNRrsRl90ti_iSfePMmETYgYpj-3-SfWo0z7Zp8fxrLp5_-7T8sP86vpitTy_mrekZmiOKBeoMbTWgnFDeOmwRry1BpexgV1NZd0xjmWHUCMQk5ZOy1Y2tTWSWXJWrQ7eNuitGqLb6bhXQTv1ZyPEtdKx3NZbRWXbGSqo5JRTypnAhOlGdy2SSLS0K67XB9cwNjvbTh1G7e9J75_0bqPW4VYJRgUkvAheHAUxfBltymrnkrHe696GMSnMIJMEUlgX9Pl_6DaMsTxzoThGUHKJSKHeHCjXdyHu9NcQfauy3pcP7qLujUuKIKimfKm_-VJTvtQxX-Q3Gb3HiQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721097913</pqid></control><display><type>article</type><title>Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Dong, Gui-Ying ; Qin, Jun-Ping ; An, Youzhong ; Kang, Yan ; Yu, Xiangyou ; Zhao, Mingyan ; Ma, Xiaochun ; Ai, Yuhang ; Xu, Yuan ; Xi, Xiuming ; Qian, Chuanyun ; Wu, Dawei ; Sun, Renhua ; Li, Shusheng ; Hu, Zhenjie ; Cao, Xiangyuan ; Zhou, Fachun ; Jiang, Li ; Lin, Jiandong ; Chen, Erzhen ; Qin, Tiehe ; He, Zhenyang ; Zhu, Jihong ; Du, Bin</creator><creatorcontrib>Dong, Gui-Ying ; Qin, Jun-Ping ; An, Youzhong ; Kang, Yan ; Yu, Xiangyou ; Zhao, Mingyan ; Ma, Xiaochun ; Ai, Yuhang ; Xu, Yuan ; Xi, Xiuming ; Qian, Chuanyun ; Wu, Dawei ; Sun, Renhua ; Li, Shusheng ; Hu, Zhenjie ; Cao, Xiangyuan ; Zhou, Fachun ; Jiang, Li ; Lin, Jiandong ; Chen, Erzhen ; Qin, Tiehe ; He, Zhenyang ; Zhu, Jihong ; Du, Bin</creatorcontrib><description>Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis of the two types of patients is similar in the ICU remains unclear.
According to the absolute and relative increase of Scr, AKI stage 1 and stage 3 patients were divided into stage 1a and 1b, stage 3a and 3b groups, respectively. Their demographics, laboratory results, clinical characteristics, and outcomes were analyzed retrospectively.
Of the 345 eligible cases, we analyzed stage 1 because stage 3a group had only one patient. Using 53 or 61.88 µmol/L as the reference Scr (Scr
ref
), no significant differences were observed in ICU mortality (P
53
=0.076, P
61.88
=0.070) or renal replacement therapy (RRT) ratio, (P
53
=0.356, P
61.88
=0.471) between stage 1a and 1b, but stage 1b had longer ICU length of stay (LOS) than stage 1a (P
53
<0.001, P
61.88
=0.032). In the Kaplan-Meier survival analysis, no differences were observed in ICU mortality between stage 1a and 1b (P
53
=0.378, P
61.88
=0.255). In a multivariate analysis, respiratory failure [HR = 4.462 (95% CI 1.144-17.401), p = 0.031] and vasoactive drug therapy [HR = 4.023 (95% CI 1.584-10.216), p = 0.003] were found to be independently associated with increased risk of death.
ICU LOS benefit was more prominent in KDIGO
SCr
AKI stage 1a patients than in stage 1 b. Further prospective studies with a larger sample size are necessary to confirm the effectiveness of reclassification.</description><identifier>ISSN: 0886-022X</identifier><identifier>EISSN: 1525-6049</identifier><identifier>DOI: 10.1080/0886022X.2021.1997761</identifier><identifier>PMID: 34860139</identifier><language>eng</language><publisher>New York: Taylor & Francis</publisher><subject>Acute kidney injury ; Clinical Study ; Cohort analysis ; Creatinine ; Drug therapy ; intensive care unit ; KDIGO ; Kidney diseases ; length of stay ; Medical prognosis ; Mortality ; Multivariate analysis ; Patients ; Prognosis ; Reclassification ; Survival analysis ; Vasoactive agents</subject><ispartof>Renal failure, 2021, Vol.43 (1), p.1569-1576</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-5715-3900 ; 0000-0002-8117-1973 ; 0000-0001-7841-2863 ; 0000-0001-6237-2895</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648037/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648037/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,4024,27502,27923,27924,27925,53791,53793,59143,59144</link.rule.ids></links><search><creatorcontrib>Dong, Gui-Ying</creatorcontrib><creatorcontrib>Qin, Jun-Ping</creatorcontrib><creatorcontrib>An, Youzhong</creatorcontrib><creatorcontrib>Kang, Yan</creatorcontrib><creatorcontrib>Yu, Xiangyou</creatorcontrib><creatorcontrib>Zhao, Mingyan</creatorcontrib><creatorcontrib>Ma, Xiaochun</creatorcontrib><creatorcontrib>Ai, Yuhang</creatorcontrib><creatorcontrib>Xu, Yuan</creatorcontrib><creatorcontrib>Xi, Xiuming</creatorcontrib><creatorcontrib>Qian, Chuanyun</creatorcontrib><creatorcontrib>Wu, Dawei</creatorcontrib><creatorcontrib>Sun, Renhua</creatorcontrib><creatorcontrib>Li, Shusheng</creatorcontrib><creatorcontrib>Hu, Zhenjie</creatorcontrib><creatorcontrib>Cao, Xiangyuan</creatorcontrib><creatorcontrib>Zhou, Fachun</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Lin, Jiandong</creatorcontrib><creatorcontrib>Chen, Erzhen</creatorcontrib><creatorcontrib>Qin, Tiehe</creatorcontrib><creatorcontrib>He, Zhenyang</creatorcontrib><creatorcontrib>Zhu, Jihong</creatorcontrib><creatorcontrib>Du, Bin</creatorcontrib><title>Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study</title><title>Renal failure</title><description>Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis of the two types of patients is similar in the ICU remains unclear.
According to the absolute and relative increase of Scr, AKI stage 1 and stage 3 patients were divided into stage 1a and 1b, stage 3a and 3b groups, respectively. Their demographics, laboratory results, clinical characteristics, and outcomes were analyzed retrospectively.
Of the 345 eligible cases, we analyzed stage 1 because stage 3a group had only one patient. Using 53 or 61.88 µmol/L as the reference Scr (Scr
ref
), no significant differences were observed in ICU mortality (P
53
=0.076, P
61.88
=0.070) or renal replacement therapy (RRT) ratio, (P
53
=0.356, P
61.88
=0.471) between stage 1a and 1b, but stage 1b had longer ICU length of stay (LOS) than stage 1a (P
53
<0.001, P
61.88
=0.032). In the Kaplan-Meier survival analysis, no differences were observed in ICU mortality between stage 1a and 1b (P
53
=0.378, P
61.88
=0.255). In a multivariate analysis, respiratory failure [HR = 4.462 (95% CI 1.144-17.401), p = 0.031] and vasoactive drug therapy [HR = 4.023 (95% CI 1.584-10.216), p = 0.003] were found to be independently associated with increased risk of death.
ICU LOS benefit was more prominent in KDIGO
SCr
AKI stage 1a patients than in stage 1 b. Further prospective studies with a larger sample size are necessary to confirm the effectiveness of reclassification.</description><subject>Acute kidney injury</subject><subject>Clinical Study</subject><subject>Cohort analysis</subject><subject>Creatinine</subject><subject>Drug therapy</subject><subject>intensive care unit</subject><subject>KDIGO</subject><subject>Kidney diseases</subject><subject>length of stay</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Reclassification</subject><subject>Survival analysis</subject><subject>Vasoactive agents</subject><issn>0886-022X</issn><issn>1525-6049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>DOA</sourceid><recordid>eNpdkstuEzEUhkcIRNPCIyBZYsMmwbfxhQWiClCiVuoCKrGzPB5P4sgZD7ankK4Q78KL8SR4SEAqK9--88nH_qvqGYILBAV8CYVgEOPPCwwxWiApOWfoQTVDNa7nDFL5sJpNzHyCTqrTlLYQolpw_Lg6IbQUIyJn1c-b7Ly7c_0aRGu8Tsl1zujsQg9y-PX9h_02-BBtmZmNjtpkG13KziSg-xYMMaz7kFwCoQOXb1cX1x-XEZxfrkAam3UM45BeAV3UOYY0WJPdrS2F2u-PNRrsRl90ti_iSfePMmETYgYpj-3-SfWo0z7Zp8fxrLp5_-7T8sP86vpitTy_mrekZmiOKBeoMbTWgnFDeOmwRry1BpexgV1NZd0xjmWHUCMQk5ZOy1Y2tTWSWXJWrQ7eNuitGqLb6bhXQTv1ZyPEtdKx3NZbRWXbGSqo5JRTypnAhOlGdy2SSLS0K67XB9cwNjvbTh1G7e9J75_0bqPW4VYJRgUkvAheHAUxfBltymrnkrHe696GMSnMIJMEUlgX9Pl_6DaMsTxzoThGUHKJSKHeHCjXdyHu9NcQfauy3pcP7qLujUuKIKimfKm_-VJTvtQxX-Q3Gb3HiQ</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Dong, Gui-Ying</creator><creator>Qin, Jun-Ping</creator><creator>An, Youzhong</creator><creator>Kang, Yan</creator><creator>Yu, Xiangyou</creator><creator>Zhao, Mingyan</creator><creator>Ma, Xiaochun</creator><creator>Ai, Yuhang</creator><creator>Xu, Yuan</creator><creator>Xi, Xiuming</creator><creator>Qian, Chuanyun</creator><creator>Wu, Dawei</creator><creator>Sun, Renhua</creator><creator>Li, Shusheng</creator><creator>Hu, Zhenjie</creator><creator>Cao, Xiangyuan</creator><creator>Zhou, Fachun</creator><creator>Jiang, Li</creator><creator>Lin, Jiandong</creator><creator>Chen, Erzhen</creator><creator>Qin, Tiehe</creator><creator>He, Zhenyang</creator><creator>Zhu, Jihong</creator><creator>Du, Bin</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>3V.</scope><scope>7T5</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-5715-3900</orcidid><orcidid>https://orcid.org/0000-0002-8117-1973</orcidid><orcidid>https://orcid.org/0000-0001-7841-2863</orcidid><orcidid>https://orcid.org/0000-0001-6237-2895</orcidid></search><sort><creationdate>2021</creationdate><title>Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study</title><author>Dong, Gui-Ying ; Qin, Jun-Ping ; An, Youzhong ; Kang, Yan ; Yu, Xiangyou ; Zhao, Mingyan ; Ma, Xiaochun ; Ai, Yuhang ; Xu, Yuan ; Xi, Xiuming ; Qian, Chuanyun ; Wu, Dawei ; Sun, Renhua ; Li, Shusheng ; Hu, Zhenjie ; Cao, Xiangyuan ; Zhou, Fachun ; Jiang, Li ; Lin, Jiandong ; Chen, Erzhen ; Qin, Tiehe ; He, Zhenyang ; Zhu, Jihong ; Du, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d3561-14781bc45a867c37139517dec2951b0f5495f6729f11b8169e4f672d9b5ec96e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute kidney injury</topic><topic>Clinical Study</topic><topic>Cohort analysis</topic><topic>Creatinine</topic><topic>Drug therapy</topic><topic>intensive care unit</topic><topic>KDIGO</topic><topic>Kidney diseases</topic><topic>length of stay</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Reclassification</topic><topic>Survival analysis</topic><topic>Vasoactive agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Gui-Ying</creatorcontrib><creatorcontrib>Qin, Jun-Ping</creatorcontrib><creatorcontrib>An, Youzhong</creatorcontrib><creatorcontrib>Kang, Yan</creatorcontrib><creatorcontrib>Yu, Xiangyou</creatorcontrib><creatorcontrib>Zhao, Mingyan</creatorcontrib><creatorcontrib>Ma, Xiaochun</creatorcontrib><creatorcontrib>Ai, Yuhang</creatorcontrib><creatorcontrib>Xu, Yuan</creatorcontrib><creatorcontrib>Xi, Xiuming</creatorcontrib><creatorcontrib>Qian, Chuanyun</creatorcontrib><creatorcontrib>Wu, Dawei</creatorcontrib><creatorcontrib>Sun, Renhua</creatorcontrib><creatorcontrib>Li, Shusheng</creatorcontrib><creatorcontrib>Hu, Zhenjie</creatorcontrib><creatorcontrib>Cao, Xiangyuan</creatorcontrib><creatorcontrib>Zhou, Fachun</creatorcontrib><creatorcontrib>Jiang, Li</creatorcontrib><creatorcontrib>Lin, Jiandong</creatorcontrib><creatorcontrib>Chen, Erzhen</creatorcontrib><creatorcontrib>Qin, Tiehe</creatorcontrib><creatorcontrib>He, Zhenyang</creatorcontrib><creatorcontrib>Zhu, Jihong</creatorcontrib><creatorcontrib>Du, Bin</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Renal failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Gui-Ying</au><au>Qin, Jun-Ping</au><au>An, Youzhong</au><au>Kang, Yan</au><au>Yu, Xiangyou</au><au>Zhao, Mingyan</au><au>Ma, Xiaochun</au><au>Ai, Yuhang</au><au>Xu, Yuan</au><au>Xi, Xiuming</au><au>Qian, Chuanyun</au><au>Wu, Dawei</au><au>Sun, Renhua</au><au>Li, Shusheng</au><au>Hu, Zhenjie</au><au>Cao, Xiangyuan</au><au>Zhou, Fachun</au><au>Jiang, Li</au><au>Lin, Jiandong</au><au>Chen, Erzhen</au><au>Qin, Tiehe</au><au>He, Zhenyang</au><au>Zhu, Jihong</au><au>Du, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study</atitle><jtitle>Renal failure</jtitle><date>2021</date><risdate>2021</risdate><volume>43</volume><issue>1</issue><spage>1569</spage><epage>1576</epage><pages>1569-1576</pages><issn>0886-022X</issn><eissn>1525-6049</eissn><abstract>Acute kidney injury (AKI) is widespread in the intensive care unit (ICU) and affects patient prognosis. According to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, the absolute and relative increases of serum creatinine (Scr) are classified into the same stage. Whether the prognosis of the two types of patients is similar in the ICU remains unclear.
According to the absolute and relative increase of Scr, AKI stage 1 and stage 3 patients were divided into stage 1a and 1b, stage 3a and 3b groups, respectively. Their demographics, laboratory results, clinical characteristics, and outcomes were analyzed retrospectively.
Of the 345 eligible cases, we analyzed stage 1 because stage 3a group had only one patient. Using 53 or 61.88 µmol/L as the reference Scr (Scr
ref
), no significant differences were observed in ICU mortality (P
53
=0.076, P
61.88
=0.070) or renal replacement therapy (RRT) ratio, (P
53
=0.356, P
61.88
=0.471) between stage 1a and 1b, but stage 1b had longer ICU length of stay (LOS) than stage 1a (P
53
<0.001, P
61.88
=0.032). In the Kaplan-Meier survival analysis, no differences were observed in ICU mortality between stage 1a and 1b (P
53
=0.378, P
61.88
=0.255). In a multivariate analysis, respiratory failure [HR = 4.462 (95% CI 1.144-17.401), p = 0.031] and vasoactive drug therapy [HR = 4.023 (95% CI 1.584-10.216), p = 0.003] were found to be independently associated with increased risk of death.
ICU LOS benefit was more prominent in KDIGO
SCr
AKI stage 1a patients than in stage 1 b. Further prospective studies with a larger sample size are necessary to confirm the effectiveness of reclassification.</abstract><cop>New York</cop><pub>Taylor & Francis</pub><pmid>34860139</pmid><doi>10.1080/0886022X.2021.1997761</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5715-3900</orcidid><orcidid>https://orcid.org/0000-0002-8117-1973</orcidid><orcidid>https://orcid.org/0000-0001-7841-2863</orcidid><orcidid>https://orcid.org/0000-0001-6237-2895</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0886-022X |
| ispartof | Renal failure, 2021, Vol.43 (1), p.1569-1576 |
| issn | 0886-022X 1525-6049 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8648037 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Acute kidney injury Clinical Study Cohort analysis Creatinine Drug therapy intensive care unit KDIGO Kidney diseases length of stay Medical prognosis Mortality Multivariate analysis Patients Prognosis Reclassification Survival analysis Vasoactive agents |
| title | Utilizing reclassification to explore characteristics and prognosis of KDIGOSCr AKI subgroups: a retrospective analysis of a multicenter prospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A18%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utilizing%20reclassification%20to%E2%80%82explore%E2%80%82characteristics%20and%20prognosis%20of%20KDIGOSCr%20AKI%20subgroups:%20a%20retrospective%20analysis%20of%20a%20multicenter%20prospective%20cohort%20study&rft.jtitle=Renal%20failure&rft.au=Dong,%20Gui-Ying&rft.date=2021&rft.volume=43&rft.issue=1&rft.spage=1569&rft.epage=1576&rft.pages=1569-1576&rft.issn=0886-022X&rft.eissn=1525-6049&rft_id=info:doi/10.1080/0886022X.2021.1997761&rft_dat=%3Cproquest_pubme%3E2606930405%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721097913&rft_id=info:pmid/34860139&rft_doaj_id=oai_doaj_org_article_49dfc484974744768236abafd1918d4f&rfr_iscdi=true |